Page last updated: 2024-12-06

dopexamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dopexamine is a synthetic dopamine agonist that was originally developed as a cardiotonic drug. It has a complex pharmacological profile, acting as a partial agonist at dopamine D1 and D2 receptors, a weak α1-adrenoceptor agonist, and an inhibitor of dopamine uptake. The compound was initially studied for its potential to improve cardiac function in patients with heart failure, as it increases cardiac output and improves left ventricular contractility. However, its clinical use has been limited due to concerns about its safety profile, including potential for arrhythmias and hypotension. Research on dopexamine continues to explore its therapeutic potential in other areas, such as in the treatment of shock, acute kidney injury, and Parkinson's disease. Despite its complex pharmacological actions, dopexamine's mechanism of action is not fully understood. Further research is needed to clarify its potential clinical applications and to determine its long-term safety.'

dopexamine: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55483
CHEMBL ID77622
CHEBI ID135507
SCHEMBL ID122233
MeSH IDM0134272

Synonyms (44)

Synonym
CHEMBL77622
fpl-60278
dopexamine (usan/inn)
D03891
86197-47-9
dopexamine
4-(2-((6-(phenethylamino)hexyl)amino)ethyl)pyrocatechol
1,2-benzenediol, 4-(2-((6-((2-phenylethyl)amino)hexyl)amino)ethyl)-
c22h32n2o2
dopexaminum [latin]
fpl 60278
dopexamina [spanish]
CHEBI:135507
L003335
NCGC00184998-01
unii-398e7z7jb5
398e7z7jb5 ,
dopexamine [usan:inn:ban]
dopexaminum
dopexamina
dtxcid9028592
tox21_113031
cas-86197-47-9
dtxsid2048666 ,
AKOS016014049
FT-0630938
SCHEMBL122233
NCGC00184998-02
tox21_113031_1
4-[2-[[6-(phenethylamino)hexyl]amino]ethyl]pyrocatechol
dopexamine [who-dd]
dopexamine [mi]
dopexamine [inn]
dopexamine [usan]
4-(2-((6-(phenethylamino)hexyl)amino)ethyl)benzene-1,2-diol
4-[2-({6-[(2-phenylethyl)amino]hexyl}amino)ethyl]benzene-1,2-diol
DB12313
4-(2-(6-(phenethylamino)hexylamino)ethyl)benzene-1,2-diol
Q5297311
4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]benzene-1,2-diol
A917656
4-[2-[[6-(phenethylamino)hexyl]amino]ethyl]-1,2-benzenediol
EN300-19767543
dopexamine-d3hydrochloride

Research Excerpts

Overview

Dopexamine is a synthetic catecholamine, which has positive inotropic and vasodilating properties. It is a substance with strong beta2-adrenergic effects and is used in the treatment of critically ill patients.

ExcerptReferenceRelevance
"Dopexamine is a dopamine analog that has been used for hemodynamic optimization in a number of clinical settings. "( Dopexamine: immunomodulatory, hemodynamic, or both?
Hollenberg, SM, 2013
)
3.28
"Dopexamine is a synthetic catecholamine, which has positive inotropic and vasodilating properties."( Hemodynamic effects of dobutamine and dopexamine after cardiopulmonary bypass in pediatric cardiac surgery.
Akintürk, H; Koch, T; Kwapisz, MM; Löhr, T; Müller, M; Neuhäuser, C; Scholz, S; Thul, J; Valeske, K; Welters, ID, 2009
)
1.35
"Dopexamine is a substance with strong beta2-adrenergic effects and is used in the treatment of critically ill patients."( Dopexamine and cellular immune functions during systemic inflammation.
Exton, M; Oberbeck, R; Schedlowski, M; Schmitz, D; Schüler, M; Wilsenack, K, 2004
)
2.49
"Dopexamine hydrochloride is a new synthetic catecholamine for intravenous use in low cardiac output states with co-existing raised systemic or pulmonary vascular resistance. "( [Dopexamine: a new dopaminergic agonist].
Martin, C; Papazian, L; Perrin, G, 1993
)
2.64
"Dopexamine hydrochloride is a synthetic dopamine analogue recently developed to improve myocardial and renal performance in patients suffering from low cardiac output states. "( Dopexamine hydrochloride in the human kidney: localization, receptor binding and effect on 3'-5'-cyclic adenosine monophosphate generation.
Amenta, F; Cavallotti, C; Napoleone, P; Ricci, A, 1993
)
3.17
"Dopexamine hydrochloride is a novel synthetic adrenergic agonist that combines the renal effects of dopamine with the hemodynamic effects of dobutatmine. "( Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting.
Butterworth, JF; James, R; MacGregor, DA; Prielipp, RC; Royster, RL; Zaloga, CP, 1994
)
2.01
"Dopexamine hydrochloride is a new dopamine analogue with action at beta 2-adrenoceptors and DA1 receptors, but it possesses no direct alpha-adrenoceptor activity."( The use of dopexamine hydrochloride to increase oxygen delivery perioperatively.
Bennett, ED; Boyd, O; Grounds, RM, 1993
)
1.4
"Dopexamine is a synthetic catecholamine with predominantly beta 2 and dopaminergic adrenergic receptor activities. "( Effects of dopexamine on hemodynamics and oxygen consumption after beta blockade in lambs.
Rogers, BW; Sziszak, TJ; Sziszak, TL; Taylor, BJ, 1993
)
2.12
"Dopexamine is a specific dopaminergic and beta2-adrenergic agonist. "( Indomethacin-induced reduction in neonatal piglet mesenteric blood flow is blunted by dopexamine.
Choe, EU; Ferrara, JJ; Flint, LM; Mero, KA, 1998
)
1.97
"Dopexamine is a synthetic vasoactive catecholamine with beneficial microcirculatory properties."( Retracted: Influence of dopexamine hydrochloride on haemodynamics and regulators of circulation in patients undergoing major abdominal surgery.
Boldt, J; Hempelmann, G; Padberg, W; Papsdorf, M; Piper, S, 1998
)
1.33
"Dopexamine is a synthetic catecholamine used for the management of low-cardiac-output states. "( Characterization of the mechanism involved in the relaxant response of dopexamine in the guinea pig pulmonary artery in vitro.
Calixto, JB; Dias, MA; Mazzuco, TL, 1999
)
1.98
"Dopexamine (DPX) is a novel synthetic agent that has potent B2-adrenoceptor and dopaminergic activity, the clinical effects of which include an increase in cardiac output and in mesenteric blood flow."( Post-treatment dopexamine infusions partially reverse reductions in cranial mesenteric blood flow and mucosal oxygenation induced by hypoxia in newborn piglets.
Aliabadi-Wahle, S; Choe, EU; Ferrara, JJ; Flint, LM, 1999
)
1.38
"Dopexamine (DX) is a commonly used catecholamine which probably exerts a selective effect at the splanchnic bed."( Impairment of renal function after cardiopulmonary bypass is not influenced by dopexamine.
Dehne, MG; Hempelmann, G; Klein, TF; Mühling, J; Osmer, C; Sablotzki, A, 2001
)
1.26
"Dopexamine hydrochloride is a new combined beta 2-adrenergic and DA1-dopaminergic receptor agonist and an inhibitor of the uptake-1 mechanism of endogenous catecholamines."( Prolonged infusion of varied doses of dopexamine hydrochloride for low cardiac output after cardiac surgery.
Santman, FW, 1992
)
1.28
"Dopexamine hydrochloride is a synthetic catecholamine proposed for the short-term treatment of heart failure and postoperative low cardiac output. "( Dopexamine hydrochloride in the human heart: receptor binding and effects on cAMP generation.
Amenta, F; Ferrante, F; Napoleone, P; Ricci, A, 1992
)
3.17
"Dopexamine hydrochloride is a new synthetic catechol that offers a unique profile of adrenergic and dopaminergic activity. "( Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study.
Elkayam, U; Gollub, SB; Haffey, KA; Miller, LW; Young, JB, 1991
)
1.96
"Dopexamine hydrochloride is a novel synthetic catecholamine, structurally related to dopamine, with marked intrinsic agonist activity at beta 2-adrenoceptors, lesser agonist activity at dopamine DA1- and DA2-receptors and beta 1-adrenoceptors, and an inhibitory action on the neuronal catecholamine uptake mechanism. "( Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.
Benfield, P; Fitton, A, 1990
)
3.16
"Dopexamine hydrochloride is a novel compound with properties of DA1-dopaminergic and beta 2-adrenergic receptor agonism and neuronal noradrenaline uptake inhibition. "( Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe congestive heart failure.
Littler, WA; Murray, RG; Tan, LB, 1991
)
1.99
"2. Dopexamine hydrochloride is a new synthetic catecholamine."( Dopexamine: studies in the general intensive care unit and after liver transplantation.
Bodenham, AR; Burns, A; Gray, PA; Park, GR, 1990
)
2.24
"Dopexamine hydrochloride is a new analog of dopamine that lowers systemic vascular resistance and has positive inotropic and chronotropic properties, but lacks the alpha-adrenoceptor agonist activity of dopamine. "( Effects of dopexamine hydrochloride on hypoxic pulmonary vasoconstriction in isolated rat lung.
Barnes, PJ; Evans, TW; McCormack, DG, 1990
)
2.11
"1. Dopexamine is a novel analogue of dopamine which is free of alpha-adrenoceptor activity and is of therapeutic value in chronic heart failure. "( The effects of dopexamine, a new dopamine analogue, on platelet function in stress.
Hendra, TJ; Smith, CC; Wagaine-Twabwe, D; Yudkin, JS, 1990
)
1.25
"Dopexamine (FPL 60278) is a new vasodilator possessing both postjunctional dopaminergic and beta 2-adrenoceptor agonist actions. "( Acute hemodynamic and neuroendocrine effects of dopexamine, a new vasodilator for the treatment of heart failure: comparison with dobutamine, captopril, and nitrate.
Bayliss, J; Poole-Wilson, P; Thomas, L, 1987
)
1.97
"Dopexamine is a novel compound that has DA1-dopaminergic and beta 2-adrenergic agonist properties capable of producing beneficial systemic and renal vasodilation. "( Beneficial haemodynamic effects of intravenous dopexamine in patients with low-output heart failure.
Littler, WA; Murray, RG; Tan, LB, 1987
)
1.97
"Dopexamine is a new dopamine receptor agonist which also inhibits the uptake of norepinephrine (NE) into sympathetic nerves. "( Potentiation by dopexamine of the cardiac responses to circulating and neuronally released norepinephrine: a possible mechanism for the therapeutic effects of the drug.
Bass, AS; Goldberg, LI; Kohli, JD; Murphy, MB, 1989
)
2.07
"Dopexamine is a newly developed sympathetic catecholamine which combines dopaminergic (DA-1) and beta 2-adrenergic agonist activity with only minor beta 1-adrenergic action. "( Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?
Drexler, H; Just, H; Meinertz, T, 1989
)
3.16
"Dopexamine is a new dopamine analogue, with combined agonist properties on dopamine receptors and the beta 2-adrenoceptor. "( Hemodynamic effects of dopexamine in patients following coronary artery bypass surgery.
Koolen, JJ; Mungroop, HE; Poelaert, JI; Van den Berg, PC, 1989
)
2.03
"Dopexamine is an agonist at peripheral dopamine receptors and at beta 2-adrenoceptors. "( Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.
Brown, RA; Dixon, J; Farmer, JB; Hall, JC; Humphries, RG; Ince, F; O'Connor, SE; Simpson, WT; Smith, GW, 1985
)
3.15
"Dopexamine (FPL 60278) is a new dopamine analogue which possesses a combination of dopamine receptor and beta-2-adrenoreceptor agonist properties. "( Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure.
Erhardt, L; Sjögren, A; Svensson, G, 1986
)
1.99
"Dopexamine is a new vasodilator with a combination of dopamine receptor and beta 2 adrenoreceptor agonist properties. "( Haemodynamic response to dopexamine hydrochloride in postinfarction heart failure: lack of tolerance after continuous infusion.
Erhardt, L; Lindvall, B; Strandberg, LE; Svenson, G, 1988
)
2.02
"Dopexamine hydrochloride is a new intravenous, short-acting agent with agonist activity at beta 2-adrenergic and DA1-dopaminergic receptors. "( Dopexamine hydrochloride in chronic congestive heart failure with improved cardiac performance without increased metabolic cost.
Chatterjee, K; De Marco, T; Kwasman, M; Lau, D, 1988
)
3.16
"Dopexamine hydrochloride is a novel beta 2- and dopaminergic-receptor agonist proposed for intravenous therapy in patients with congestive heart failure. "( Inotropic, vascular and neuroendocrine effects of dopexamine hydrochloride and comparison with dobutamine.
Jaski, BE; Peters, C, 1988
)
1.97
"Dopexamine hydrochloride is an effective and well-tolerated sympathomimetic agent that increases cardiac index while promoting vasodilatation."( Hemodynamic effects of dopexamine hydrochloride infusions of 48 to 72 hours' duration for severe congestive heart failure.
Emmot, WW; Gollub, SB; Hassanein, K; Johnson, DE; Sights, KA; Vacek, JL; Wilson, DB, 1988
)
1.31

Effects

Dopexamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses. At dosage rate studied (4 micrograms/kg/min), its administration was associated with a number of undesirable adverse effects.

Dopexamine has one-third the potency of dopamine in stimulating the vascular DA1-receptor in the dog, resulting in a fall in renal vascular resistance of 20% at 2.3 X 10(-8) mol kg-1 (i.a.) It has been shown to reduce both mortality and morbidity in major surgery when it is used as part of a protocol to increase oxygen delivery.

ExcerptReferenceRelevance
"Dopexamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, at the dosage rate studied (4 micrograms/kg/min), its administration was associated with a number of undesirable adverse effects which could preclude its clinical use."( Temporal effects of an infusion of dopexamine hydrochloride in horses anesthetized with halothane.
Blissitt, KJ; Clutton, RE; Molony, V; Young, LE, 1997
)
2.02
"Dopexamine has a chronotropic effect and results in a decrease in systemic vascular resistance."( The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist.
Foulds, R; Jaski, BE; Serruys, PW; Wijns, W, 1986
)
1.26
"Dopexamine has been shown to reduce both mortality and morbidity in major surgery when it is used as part of a protocol to increase oxygen delivery in the perioperative period. "( Dopexamine has no additional benefit in high-risk patients receiving goal-directed fluid therapy undergoing major abdominal surgery.
Davies, SJ; Wilson, RJ; Yates, D, 2011
)
3.25
"Dopexamine has assumed effects on carbohydrate, fat and protein metabolism."( Effects of dopexamine in comparison with fenoterol on carbohydrate, fat and protein metabolism in healthy volunteers.
Ensinger, H; Geisser, W; Georgieff, M; Hofbauer, H; Vogt, J; Wachter, U, 2004
)
1.43
"Dopexamine has no or only weak effects on carbohydrate metabolism, its effects on fat and protein metabolism are comparable to those of fenoterol. "( Effects of dopexamine in comparison with fenoterol on carbohydrate, fat and protein metabolism in healthy volunteers.
Ensinger, H; Geisser, W; Georgieff, M; Hofbauer, H; Vogt, J; Wachter, U, 2004
)
2.16
"Dopexamine hydrochloride has interesting vasodilator properties, with marked intrinsic agonist activity at beta-2 adrenoreceptors and a lesser agonist activity at dopaminergic receptors (DA1 and DA2)."( [Dopexamine: a new dopaminergic agonist].
Martin, C; Papazian, L; Perrin, G, 1993
)
1.92
"Dopexamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, at the dosage rate studied (4 micrograms/kg/min), its administration was associated with a number of undesirable adverse effects which could preclude its clinical use."( Temporal effects of an infusion of dopexamine hydrochloride in horses anesthetized with halothane.
Blissitt, KJ; Clutton, RE; Molony, V; Young, LE, 1997
)
2.02
"Dopexamine has been suggested to improve splanchnic perfusion but because these effects remain somewhat controversial, there is as yet no reason for a general recommendation for dopexamine in septic patients."( Haemodynamic management of a patient with septic shock.
Meier-Hellmann, A; Reinhart, K; Sakka, SG, 2000
)
1.03
"Dopexamine has been suggested for improvement of splanchnic perfusion, but since these effects remain somewhat controversial there are no current grounds for a general recommendation in favour of dopexamine in septic patients."( Catecholamines and splanchnic perfusion.
Meier-Hellmann, A; Reinhart, K; Sakka, SG, 2000
)
1.03
"Dopexamine hydrochloride has no affinity for the uptake-2 mechanism in this tissue."( Inhibition of 3H-noradrenaline accumulation by dopexamine hydrochloride in the isolated aorta of the rabbit.
Nedergaard, OA, 1989
)
1.26
"Dopexamine has approximately one-third the potency of dopamine in stimulating the vascular DA1-receptor in the dog, resulting in a fall in renal vascular resistance of 20% at 2.3 X 10(-8) mol kg-1 (i.a.)."( Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.
Brown, RA; Dixon, J; Farmer, JB; Hall, JC; Humphries, RG; Ince, F; O'Connor, SE; Simpson, WT; Smith, GW, 1985
)
2.43
"Dopexamine has a chronotropic effect and results in a decrease in systemic vascular resistance."( The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist.
Foulds, R; Jaski, BE; Serruys, PW; Wijns, W, 1986
)
1.26

Actions

Dopexamine evoked an increase in cardiac index preoperatively. The dopexamine-induced increase in gastric mucosal oxygenation was mediated by beta2-adrenoceptors, which explains the superior effects of dopamine to dopamine on mu-Hbo2.

ExcerptReferenceRelevance
"Dopexamine evoked an increase in cardiac index preoperatively. "( The effect of dopexamine on regional tissue oxygenation, systemic inflammation and amino acid exchange in major abdominal surgery.
Ruokonen, ET; Suojaranta-Ylinen, RT; Takala, JA, 2000
)
2.11
"The dopexamine-induced increase in gastric mucosal oxygenation was mediated by beta2-adrenoceptors, which explains the superior effects of dopexamine to dopamine on mu-Hbo2."( Dopexamine but not dopamine increases gastric mucosal oxygenation during mechanical ventilation in dogs.
Fournell, A; Loer, SA; Picker, O; Scheeren, TW; Schwarte, LA, 2002
)
2.24
"Dopexamine-induced increase in heart rate was potentiated by parasympathetic and ganglionic blockade."( Inotropic mechanisms of dopexamine hydrochloride in horses.
Muir, WW, 1992
)
1.31
"With dopexamine, the increase in renal blood flow (66%) was less than the increase in cardiac index, while renal vascular resistance and systemic vascular resistance declined to almost the same extent."( Cardiovascular and renal haemodynamic effects of dopexamine: comparison with dopamine.
Henning, H; Sonntag, H; Stephan, H; Yoshimine, K, 1990
)
0.99
"Dopexamine, because it combines some of the properties of dopamine and salbutamol, may have a role in the management of severe low output cardiac failure."( Acute hemodynamic and neuroendocrine effects of dopexamine, a new vasodilator for the treatment of heart failure: comparison with dobutamine, captopril, and nitrate.
Bayliss, J; Poole-Wilson, P; Thomas, L, 1987
)
1.25

Treatment

Dopexamine treatment was associated with impaired organ function and an increased duration of ventilation and ICU stay compared with patients who received dopamine treatment. Pretreatment with dopexamine, a dopamine receptor (DA1) and beta 2 adrenoceptor agonist significantly enhanced survival upto 70%.

ExcerptReferenceRelevance
"The dopexamine treated patients had lower myocardial oxygen consumption (9310+/-2243 mmHg O2/sec vs. "( Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
Arlt, A; El Mokhtari, NE; Lins, M; Meissner, A, 2008
)
1.11
"Dopexamine treatment was associated with impaired organ function and an increased duration of ventilation and ICU stay compared with patients who received dopamine treatment. "( Is dopexamine superior to dopamine in the treatment of multiple trauma patients--a prospective, double-blind, randomised study.
Baur, H; Grotz, MR; Hildebrand, F; Krettek, C; Mahlke, L; Pape, HC; Probst, C; van Griensven, M, 2010
)
2.42
"The dopexamine treated patients had lower myocardial oxygen consumption (9310 +/- 2243 mmHg O2/sec vs. "( Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
Arlt, A; El Mokhtari, NE; Lins, M; Meissner, A, 2007
)
1.1
"The dopexamine treated patients had a significantly longer period of low pHi but the pH-gap i.e."( Effect of dopexamine on calculated low gastric intramucosal pH following valve replacement.
Gårdebäck, M; Ohquist, G; Settergren, G; Tirén, C, 1995
)
1.17
"Dopexamine treatment was associated with higher lactate levels and increased heart rate (P<0.05) during aortic cross-clamping."( Supraceliac aortic cross-clamping and declamping. Effects of dopexamine and dopamine on systemic and mesenteric hemodynamics, metabolism and intestinal tonometry in a rat model.
Studer, W; Wu, X, 2000
)
1.27
"Pretreatment with dopexamine, a dopamine receptor (DA1) and beta 2 adrenoceptor agonist significantly enhanced survival upto 70%."( Studies on the pharmacological interventions to prevent oxygen free radical (OFR)-mediated toxicity; effects of dopexamine, a DA1 receptor and beta 2 adrenoceptor agonist.
Jacinto, SM; Jandhyala, BS; Lokhandwala, MF, 1994
)
0.82
"Rats treated with dopexamine had higher renal Na+ and K+ excretion than dopamine-treated rats."( Comparative effects of dopexamine and dopamine on glycerol-induced acute renal failure in rats.
Eleno, N; Gömez-Garre, DN; López-Farré, A; López-Novoa, JM, 1996
)
0.93
"Treatment with dopexamine does not improve the pancreatic microcirculation or reduce the extent of acinar cell injury in acute necrotising pancreatitis and is therefore unlikely to be of benefit in patients with pancreatitis."( Effects of dopexamine on acute necrotising pancreatitis in rats.
Alhan, E; Cicek, R; Deger, O; Erçin, C; Küçüktülü, U, 2001
)
1.05

Toxicity

ExcerptReferenceRelevance
" Very few patients developed adverse reactions related to dopexamine, although five patients randomized to receive high dose and three patients randomized to receive intermediate dose dopexamine required dose reduction because hemodynamic variables exceeded arbitrary safety limits or the patients developed symptoms related to the study medication."( Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study.
Elkayam, U; Gollub, SB; Haffey, KA; Miller, LW; Young, JB, 1991
)
0.76

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Clonidine, dobutamine, and dopexamine at high dosage suppress the gastric mucosal vasodilator response to acid back diffusion, which is an important defense mechanism.

ExcerptRelevanceReference
"The hemodynamic effects of dopexamine hydrochloride and dobutamine were compared during dose-response infusions of dopexamine (1."( Usefulness of dopexamine hydrochloride versus dobutamine in chronic congestive heart failure and effects on hemodynamics and urine output.
Baumann, G; Felix, SB; Filcek, SA, 1990
)
0.94
" Nausea and vomiting are the most frequently reported adverse effects, and respond to dosage reduction."( Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.
Benfield, P; Fitton, A, 1990
)
1.72
" A four-point dose-response curve was prepared for dopexamine from 1 microgram/kg/min to 4 micrograms/kg/min."( [Acute reduction of increased atrial natriuretic peptide level and cyclic guanosine monophosphate in patients with chronic heart failure caused by beta-adrenergic stimulation with dopexamine hydrochloride. Correlation with hemodynamic parameters].
Baumann, G; Blömer, H; Gerzer, R; Kerscher, M; Stangl, K; Weil, J, 1990
)
0.72
"The hemodynamic dose-response effects of intravenous dopexamine hydrochloride (0."( Hemodynamic comparison of dopexamine hydrochloride and dopamine in ischemic left ventricular dysfunction.
Frais, MA; Jackson, NC; Taylor, SH, 1988
)
0.82
" The aim of this study was to evaluate the short-term hemodynamic effects of dopexamine at different dosage rates in postoperative coronary artery bypass (CABG) patients, especially with respect to the right ventricle, using a right ventricular ejection fraction pulmonary artery catheter."( Hemodynamic effects of dopexamine in patients following coronary artery bypass surgery.
Koolen, JJ; Mungroop, HE; Poelaert, JI; Van den Berg, PC, 1989
)
0.82
" The aim of our study was to evaluate the short-term haemodynamic effects of dopexamine administered by intravenous infusion at different dosage rates."( Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure.
Erhardt, L; Sjögren, A; Svensson, G, 1986
)
0.78
" Initially, the drug was infused at increasing dosage to achieve a maximal tolerated dose and then titrated to maintain acceptable clinical parameters over the next 48 to 72 hours."( Hemodynamic effects of dopexamine hydrochloride infusions of 48 to 72 hours' duration for severe congestive heart failure.
Emmot, WW; Gollub, SB; Hassanein, K; Johnson, DE; Sights, KA; Vacek, JL; Wilson, DB, 1988
)
0.59
" The displacements of the dose-response curves for fenoldopam, dopexamine and dopamine were, however, non-parallel with significant depression of the maxima to 30."( Atypical antagonism of D1-receptor-mediated vasodilator response in the perfused kidney by SCH23390.
Broadley, KJ; Martin, SW, 1995
)
0.53
" alpha-Adrenoceptor blockade by dopexamine and fenoldopam was confirmed by the parallel displacement of dose-response curves for the vasopressor responses to noradrenaline."( Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.
Broadley, KJ; Martin, SW, 1995
)
0.88
" In anaesthetized dogs (n = 5), dose-response curves were obtained by intravenous infusion of increasing doses of dopexamine (5-20 micrograms kg-1 min-1)."( Cardiovascular actions of dopexamine in anaesthetized and conscious dogs.
Abdul-Hussein, N; Chang, DH; Einstein, R; Matthews, R; Richardson, DP; Wong, TW, 1994
)
0.8
"8 micrograms dopamine or dopexamine during 1 min, and 2) by dose-response curves."( Comparison of effects of dopamine hydrochloride and dopexamine hydrochloride on abdominal and femoral hemodynamics in anesthetized dogs.
Brouwer, FA; Charbon, GA; Heethaar, J; Heethaar, RM; van Kesteren, RG, 1993
)
0.84
"Prospective dose-response study with each animal serving as it own control."( Effects of dopexamine on hemodynamics and oxygen consumption after beta blockade in lambs.
Rogers, BW; Sziszak, TJ; Sziszak, TL; Taylor, BJ, 1993
)
0.68
" Dose-response curves for dopexamine, isoprenaline, noradrenaline and impromidine on heart rate, blood pressure and myocardial contractility (dP/dt:integrated isometric tension) were obtained in untreated dogs and compared to those measured in dogs which had been pretreated with propranolol (8 mg kg-1 day-1), atenolol (6 mg kg-1 day-1), isoprenaline (0."( Changes in cardiovascular responsiveness to dopexamine and beta 1- and beta 2-adrenoceptor function after the chronic treatment of beta-adrenoceptor antagonists and agonists in anaesthetized dogs.
Chang, DH; Einstein, R, 1996
)
0.86
"Dopexamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, at the dosage rate studied (4 micrograms/kg/min), its administration was associated with a number of undesirable adverse effects which could preclude its clinical use."( Temporal effects of an infusion of dopexamine hydrochloride in horses anesthetized with halothane.
Blissitt, KJ; Clutton, RE; Molony, V; Young, LE, 1997
)
2.02
"From the selected studies, information was obtained regarding patient population, dosing regimen, duration of study, and effects on splanchnic blood flow (SBF), splanchnic oxygenation, and pHi."( Effects of vasoactive drugs on gastric intramucosal pH.
Créteur, J; DeBacker, D; Silva, E; Vincent, JL, 1998
)
0.3
"5 microg/kg/min, with further improvement as the dosage increased."( Effects of dopamine, dobutamine, dopexamine, phenylephrine, and saline solution on intramuscular blood flow and other cardiopulmonary variables in halothane-anesthetized ponies.
Alibhai, HI; Clarke, KW; Lee, YH; Song, D, 1998
)
0.58
"Clonidine, dobutamine, and dopexamine at high dosage suppress the gastric mucosal vasodilator response to acid back diffusion, which is an important defense mechanism."( Differential effects of clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach.
Holzer, P; Painsipp, E, 2001
)
0.85
" This effect was independent of the dosage and the ventilation mode."( Dopexamine but not dopamine increases gastric mucosal oxygenation during mechanical ventilation in dogs.
Fournell, A; Loer, SA; Picker, O; Scheeren, TW; Schwarte, LA, 2002
)
1.76
" Dosage of norepinephrine could be reduced by dopexamine infusion."( [The effect of dopexamine and iloprost on plasma disappearance rate of indocyanine green in patients in septic shock].
Birnbaum, J; Gründling, M; Kox, WJ; Krausch, D; Lehmann, C; Spies, C; Taymoorian, K; Wauer, H, 2003
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
catecholamine4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency16.36840.002541.796015,848.9004AID1347395; AID1347397; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency4.05590.01846.806014.1254AID624172; AID743262
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency31.67680.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency8.61520.000714.592883.7951AID1259369; AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.88320.000657.913322,387.1992AID1259377
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.73770.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.49150.003041.611522,387.1992AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.60070.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.31960.001530.607315,848.9004AID1224848; AID1224849; AID1259401; AID1259403
cytochrome P450 2D6Homo sapiens (human)Potency24.54540.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.03510.001628.015177.1139AID1224843; AID1224895
Histone H2A.xCricetulus griseus (Chinese hamster)Potency55.19650.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.68520.000323.4451159.6830AID743065; AID743066; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency17.77870.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (306)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (16.67)18.7374
1990's155 (50.65)18.2507
2000's77 (25.16)29.6817
2010's16 (5.23)24.3611
2020's7 (2.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.46 (24.57)
Research Supply Index5.98 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index56.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials76 (23.97%)5.53%
Reviews29 (9.15%)6.00%
Case Studies3 (0.95%)4.05%
Observational0 (0.00%)0.25%
Other209 (65.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study [NCT01418118]Phase 425 participants (Actual)Interventional2008-10-31Completed
Prospective, Randomized Study on Two Parallel Groups Comparing Dopexamine and Norepinephrine in Combination to Epinephrine Alone on Systemic and Pulmonary Hemodynamics, Gastric Mucosal Perfusion, and Oxidative Stress in Septic Shock [NCT00134212]Phase 220 participants Interventional2002-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]